• A drug shortage refresher: How and why they happen

    Drug shortages can happen for a plethora of reasons, but sometimes there's a "gap in knowledge" between manufacturers and regulatory agencies, according to FDA expert Emily Thakur. 
  • Mark Cuban scrambled to make payroll for Cost Plus amid Silicon Valley Bank collapse

    When Silicon Valley Bank collapsed March 10, Mark Cuban joined hundreds of tech company executives scrambling to recover funds and make payroll, but he considers himself lucky, according to Fortune.
  • Kroger mail-order pharmacy service 'improperly' shared patient data, chain says

    No financial or clinical information was affected in January when "certain patients' names and email addresses were improperly shared" between Kroger's postal prescription service and its grocery business, the company said March 10. 
  • VA OKs payment for Alzheimer's drug Leqembi

    The Department of Veterans Affairs announced it will cover Leqembi, the Alzheimer's drug manufactured by Eisai  and Biogen, which received accelerated approval from the FDA in January, according to a March 13 company news release.
  • $21B opioid settlement is 'disrupting patient care,' APhA CEO says

    A $21 billion settlement between 46 attorneys general and three pharmaceutical distributors — AmerisourceBergen, Cardinal Health and McKesson — may be leading to more drug supply issues, The New York Times reported March 13. 
  • Patients question Adderall's efficacy

    A growing number of patients taking Adderall, a drug for attention-deficit/hyperactivity disorder, are questioning whether the treatment works, The New York Times reported March 13. 
  • Shortages of ER staple drugs increase

    Shortages of several key drugs used in emergency department care continue to create difficulties for practitioners and patients. Pharmaceutical companies cite increased demand, supply issues and manufacturing delays as key reasons for the shortages. 
  • Cleveland Clinic's pharmacy leader becomes vice president at ASHP

    The American Society of Health-System Pharmacists named Samuel Calabrese, the chief pharmacy officer of Cleveland Clinic, to be its next vice president of accreditation services. 
  • New York pressures retail pharmacies to provide abortion pills

    New York Gov. Kathy Hochul and Attorney General Letitia James asked CVS, Walgreens and Rite Aid to promise they will sell the abortion medication mifepristone as other state attorneys general work to block the drug's distribution. 
  • Shortage of 88% of local anesthetics sees another delay

    The ongoing shortage of local anesthetics, including bupivacaine and lidocaine solutions, has been extended, drugmakers told the American Society of Health-System Pharmacists. 
  • Eli Lilly to halt development of Alzheimer's treatment candidate

    Eli Lilly is halting development of solanezumab after it failed to slow cognitive decline in a study of patients at risk of Alzheimer's disease, the drugmaker said March 8. 
  • Essentia Health to open new 16,000-square-foot clinic, pharmacy combo

    Duluth, Minn.-based Essentia Health announced new plans to open a 16,000-square-foot clinic and drive-through pharmacy in Staples, Minn.
  • AHA pushes back on new 340B alliance

    Community health centers, healthcare advocacy groups and a pharmaceutical lobby created an alliance aimed at protecting 340B, a drug-pricing program for eligible hospitals. Hospitals aren't a fan of the alliance.
  • California rescinds $54M deal with Walgreens

    California Gov. Gavin Newsom withdrew a contract with Walgreens worth $54 million on March 8 after the national pharmacy chain shared conflicting plans for dispensing abortion pills. 
  • FDA chimes in on albuterol shortage

    In a March 8 Twitter thread, the FDA acknowledged it's aware of a potential drug supply disruption after Gurnee, Ill.-based Akorn Operating Co. closed in late February. 
  • Amoxicillin shortage continues as resupply dates are delayed again

    An ongoing national shortage of amoxicillin has again been further exacerbated by resupply delays.
  • Drugmaker to pull only preterm birth drug from market

    Covis Pharma will stop selling Makena, the only FDA-approved drug to prevent preterm births, months after a panel voted 14-1 to retract the treatment, according to The Wall Street Journal.
  • 5 Ozempic updates

    Ozempic, a diabetes treatment that has caught the attention of Elon Musk, TikTokers and WeightWatchers for its off-label use of weight loss, has landed in five recent headlines: 
  • Moderna may test its bird flu, mpox vaccines in humans in 2023

    Moderna is eyeing testing two vaccine candidates, one for mpox and another for bird flu, in humans later this year, Bloomberg reported March 6. 
  • Cuban breaks into brand-name drug market

    Mark Cuban Cost Plus Drug Co. has entered into an agreement with IBSA Pharma to sell Tirosint, a medication for hypothyroidism. It will be the first brand-name drug offered by Mr. Cuban's pharmacy.

Featured Whitepapers

Featured Webinars